BGI Genomics Co., Ltd. (300676.SZ)
CNY 49.18
(-0.06%)
CNY 49.18
(-0.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 150.64 Million CNY | -90.51% |
| 2022 | 1.65 Billion CNY | -8.98% |
| 2021 | 1.82 Billion CNY | -27.03% |
| 2020 | 2.49 Billion CNY | 656.73% |
| 2019 | 330.12 Million CNY | -31.0% |
| 2018 | 478.41 Million CNY | -4.98% |
| 2017 | 503.5 Million CNY | 31.69% |
| 2016 | 382.34 Million CNY | 25.81% |
| 2015 | 303.9 Million CNY | 467.42% |
| 2014 | 53.55 Million CNY | -73.09% |
| 2013 | 199.02 Million CNY | 90.67% |
| 2012 | 104.38 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.86 Million CNY | -13.09% |
| 2024 Q3 | -148.12 Million CNY | -7851.18% |
| 2024 Q1 | -1.64 Million CNY | -103.25% |
| 2023 Q3 | 36.27 Million CNY | 89.13% |
| 2023 FY | 157.42 Million CNY | -90.51% |
| 2023 Q1 | 51.29 Million CNY | -74.94% |
| 2023 Q2 | 19.17 Million CNY | -62.61% |
| 2023 Q4 | 50.68 Million CNY | 39.73% |
| 2022 FY | 1.65 Billion CNY | -8.98% |
| 2022 Q4 | 204.66 Million CNY | 22.7% |
| 2022 Q3 | 166.8 Million CNY | -48.53% |
| 2022 Q2 | 324.06 Million CNY | -17.44% |
| 2022 Q1 | 392.53 Million CNY | 191.63% |
| 2021 Q2 | 674.98 Million CNY | 8.72% |
| 2021 Q4 | 134.59 Million CNY | -65.7% |
| 2021 FY | 1.82 Billion CNY | -27.03% |
| 2021 Q3 | 392.4 Million CNY | -41.86% |
| 2021 Q1 | 620.84 Million CNY | 182.58% |
| 2020 FY | 2.49 Billion CNY | 656.73% |
| 2020 Q1 | 166.92 Million CNY | 1950.29% |
| 2020 Q2 | 1.84 Billion CNY | 1003.39% |
| 2020 Q3 | 1.24 Billion CNY | -32.61% |
| 2020 Q4 | -751.81 Million CNY | -160.57% |
| 2019 Q4 | 8.14 Million CNY | -91.21% |
| 2019 FY | 330.12 Million CNY | -31.0% |
| 2019 Q3 | 92.65 Million CNY | -19.4% |
| 2019 Q2 | 114.96 Million CNY | 0.52% |
| 2019 Q1 | 114.36 Million CNY | 40.44% |
| 2018 FY | 478.41 Million CNY | -4.98% |
| 2018 Q1 | 125.32 Million CNY | 30.98% |
| 2018 Q2 | 128.49 Million CNY | 2.52% |
| 2018 Q3 | 143.16 Million CNY | 11.42% |
| 2018 Q4 | 81.43 Million CNY | -43.12% |
| 2017 Q1 | 110.97 Million CNY | 89.84% |
| 2017 Q2 | 139.41 Million CNY | 25.63% |
| 2017 Q3 | 157.42 Million CNY | 12.92% |
| 2017 Q4 | 95.68 Million CNY | -39.22% |
| 2017 FY | 503.5 Million CNY | 31.69% |
| 2016 FY | 382.34 Million CNY | 25.81% |
| 2016 Q4 | 58.45 Million CNY | -56.94% |
| 2016 Q3 | 135.77 Million CNY | 41.26% |
| 2016 Q2 | 96.11 Million CNY | 4.48% |
| 2016 Q1 | 91.99 Million CNY | 0.0% |
| 2015 FY | 303.9 Million CNY | 467.42% |
| 2015 Q1 | 37.94 Million CNY | 0.0% |
| 2015 Q2 | 37.94 Million CNY | 0.0% |
| 2014 FY | 53.55 Million CNY | -73.09% |
| 2013 FY | 199.02 Million CNY | 90.67% |
| 2012 FY | 104.38 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | 84.907% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion CNY | 93.942% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | 49.255% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | 74.633% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | 46.026% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | 54.507% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | 72.566% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | -253.639% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | 49.991% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 210.915% |